Sun Pharma, Zydus recall products in US
The US Food and Drug Administration (USFDA) has said that Sun Pharma and Zydus Pharmaceuticals are recalling products in the US market due to manufacturing issues.
In its latest Enforcement Report, the US health regulator said the New Jersey-based Sun Pharmaceutical Industries, Inc, is recalling 9,840 bottles of morphine sulphate extended-release tablets for “Failed Dissolution Specifications”.
Revealing that the company initiated the Class-II nationwide (US) recall on February 6, 2025, the USFDA reported that Zydus Pharmaceuticals (USA) Inc is recalling a lot of Nelarabine Injection, used in the treatment of certain cancers, in the US.
“The company is recalling 36,978 vials of Nelarabine Injection in strength of 250mg/50mL, (5mg/mL) for “Failed Impurities/ Degradation Specifications”, it informed, while divulging that the company initiated the Class II recall in February.
According to the USFDA, Zydus is also recalling 1,893 vials of the drug in strength of 250mg/50mL, (5mg/mL).
“The company initiated the Class-II nationwide recall on February 13 this year,” it said, while divulging that a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Pertinentmt, the Indian pharmaceutical companies supply a substantial proportion of drugs to US residents, with four out of ten of all prescriptions filled in the US in 2022 being supplied by Indian companies, according to industry estimates.
“Overall, medicines from Indian companies provided USD 219 billion in savings to the US healthcare system in 2022 and a total of USD 1.3 trillion between 2013 and 2022,” the industry estimates, while adding that the generic drugs from Indian companies are expected to generate an additional USD 1.3 trillion in savings over the next five years.
